Display options
Cite
Ahmann A. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. Drugs Context. 2015;4:212288doi: 10.7573/dic.212288.
Ahmann, A. (2015). Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. Drugs in context, 4212288. https://doi.org/10.7573/dic.212288
Ahmann, Andrew. "Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin." Drugs in context vol. 4 (2015): 212288. doi: https://doi.org/10.7573/dic.212288
Ahmann A. Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. Drugs Context. 2015 Nov 11;4:212288. doi: 10.7573/dic.212288. eCollection 2015. PMID: 26633984; PMCID: PMC4654596.
Copy Download .nbib Format: NLM
Share it on

Drugs Context. 2015 Nov 11;4:212288. doi: 10.7573/dic.212288. eCollection 2015.

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.

Drugs in context

Andrew Ahmann

Affiliations

  1. Oregon Health & Science University, Portland, OR, USA.

PMID: 26633984 PMCID: PMC4654596 DOI: 10.7573/dic.212288

Abstract

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. This review evaluates a 78-week, randomized, double-blind, placebo-controlled trial investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to basal insulin in patients with inadequate glycemic control on basal insulin, with or without metformin and/or a sulfonylurea. Empagliflozin added on to basal insulin resulted in significant and sustained reductions in glycated hemoglobin (HbA1c) levels compared with placebo. Empagliflozin has previously been shown to induce weight loss, and was associated with sustained weight loss in this study. This combination therapy was well tolerated, with similar levels of hypoglycemic adverse events in the empagliflozin and placebo groups over the 78-week treatment period. Urinary tract infections and genital infections, side effects associated with SGLT2 inhibitors, were reported more commonly in the empagliflozin group; however, such events led to treatment discontinuation in very few patients. These findings suggest that, with their complementary mechanisms of action, empagliflozin added on to basal insulin may be a useful treatment option in patients on basal insulin who need additional glycemic control without weight gain.

Keywords: blood glucose; body weight; combination therapy; empagliflozin; hypoglycemic agents; insulin; sodium glucose cotransporter 2; type 2 diabetes mellitus

References

  1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
  2. Diabetes Care. 2010 Feb;33(2):240-5 - PubMed
  3. N Engl J Med. 2009 Oct 29;361(18):1736-47 - PubMed
  4. Diabetes Obes Metab. 2014 Feb;16(2):124-36 - PubMed
  5. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  6. Diabet Med. 2012 May;29(5):682-9 - PubMed
  7. QJM. 2007 Jun;100(6):345-50 - PubMed
  8. Diabetes. 2009 Apr;58(4):773-95 - PubMed
  9. J Am Soc Hypertens. 2014 May;8(5):330-9 - PubMed
  10. Endocr Rev. 2011 Aug;32(4):515-31 - PubMed
  11. Diabetes Care. 2014 Jul;37(7):1815-23 - PubMed
  12. J Diabetes. 2015 Jul;7(4):448-61 - PubMed
  13. Drug Des Devel Ther. 2014 Sep 11;8:1335-80 - PubMed
  14. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81 - PubMed
  15. Diabetes Care. 2015 Sep;38(9):1680-6 - PubMed
  16. Diabetes Metab. 2012 Apr;38(2):89-101 - PubMed
  17. J Behav Med. 2008 Jun;31(3):213-24 - PubMed
  18. Diabet Med. 2014 Nov;31(11):1293-300 - PubMed
  19. J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9 - PubMed
  20. Diabetes Care. 2013 Aug;36 Suppl 2:S226-32 - PubMed
  21. Int J Clin Pharm. 2014 Jun;36(3):488-97 - PubMed
  22. Diabetes Care. 2015 Mar;38(3):420-8 - PubMed
  23. Diabetes Care. 2001 Apr;24(4):758-67 - PubMed
  24. N Engl J Med. 2015 Nov 26;373(22):2117-28 - PubMed
  25. Int J Gen Med. 2013 Dec 04;6:877-95 - PubMed
  26. Diabetes Care. 2008 Feb;31 Suppl 2:S125-30 - PubMed
  27. Australas Med J. 2014 Oct 31;7(10):405-15 - PubMed
  28. Diabetes Care. 2015 Mar;38(3):403-11 - PubMed
  29. Diabetes Obes Metab. 2015 Oct;17(10):936-48 - PubMed
  30. Diabetes Care. 2015 Sep;38(9):1638-42 - PubMed

Publication Types